Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies-Reference-Cited by-同舟云学术

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

Published:2017-06-20 Issue:8 Volume:9 Page:1067-1087
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Freedman Joshua D¹,Hagel Joachim¹,Scott Eleanor M¹,Psallidas Ioannis²,Gupta Avinash³,Spiers Laura³,Miller Paul³,Kanellakis Nikolaos²^ORCID,Ashfield Rebecca⁴,Fisher Kerry D¹,Duffy Margaret R¹,Seymour Leonard W¹^ORCID

Affiliation:

1. Department of Oncology University of Oxford Oxford UK

2. Oxford Centre for Respiratory Medicine Oxford University Hospitals NHS Trust Oxford UK

3. Churchill Hospital Oxford University Hospital NHS Trust Oxford UK

4. Jenner Institute University of Oxford Oxford UK

Funder

Cancer Research UK

Medical Research Council

Kay Kendall Leukaemia Fund

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201707567

Reference37 articles.

1. Relationship between CD107a expression and cytotoxic activity

2. Bispecific T-Cell Engaging Antibodies for Cancer Therapy: Figure 1.

3. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

4. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g;Boyum A;Scand J Clin Lab Invest Suppl,1968

5. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-02

2. Molecular biology of canine parainfluenza virus V protein and its potential applications in tumor immunotherapy;Frontiers in Microbiology;2023-12-20

3. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects;Frontiers in Immunology;2023-12-15

4. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment;Frontiers in Immunology;2023-12-01

5. Potential targeting of the tumor microenvironment to improve cancer virotherapy;Pharmacology & Therapeutics;2023-10